Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
DOI: | 10.2147/CEG.S263685 |
Texto Completo: | http://dx.doi.org/10.2147/CEG.S263685 http://hdl.handle.net/11449/200908 |
Resumo: | Background: Hidradenitis suppurativa is a chronic inflammatory skin disorder associated with inflammatory bowel disease. However, it can arise as a paradoxical side effect of antiTNF treatment. Methods: The article reports on three patients with Crohn’s disease who developed hidradenitis suppurativa during the treatment with adalimumab. Results: Case 1: A 38-year-old female exhibited an infiltrative lesion in the inguinal region and vulva, consistent with hidradenitis suppurativa, after three months of adalimumab. These lesions were treated with partial vulvectomy. Case 2: After adalimumab treatment, a 27-year-old female, originally diagnosed with ileocolonic Crohn’s disease, went into clinical and endoscopic remission. The patient eventually presented two hyperchromic nodules in the inguinal region, which were diagnosed as hidradenitis suppurativa. The patient showed improvement after treatment with oral doxycycline and local therapy. Case 3: A 34-year-old female with fistulizing and stenosing ileocolonic Crohn’s disease, started adalimumab in 2010, with optimization in 2015. One year after, the patient developed bilateral, erythematous, hardened, inguinal nodulations with purulent drainage, consistent with hidradenitis suppurativa. Treatment with oral doxycycline, fusidic acid, and infiltration with triamcinolone resulted in partial improvement of the lesions. In 2018, the lesions deteriorate. The patient underwent surgical treatment. Conclusion: Patients with inflammatory bowel disease are more likely to the development of other mediated inflammatory diseases, such as hidradenitis suppurativa. Hidradenitis suppurativa may appear as a paradoxical reaction to anti-TNF therapy. Clinical teams must be aware of this type of complication. Early diagnosis and treatment are essential for controlling the disease and preventing the onset of complications. |
id |
UNSP_e8129b977af0f2f466a4ba071218e630 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/200908 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease?AdalimumabCrohn’s diseaseHidradenitis suppurativaInflammatory bowel diseaseBackground: Hidradenitis suppurativa is a chronic inflammatory skin disorder associated with inflammatory bowel disease. However, it can arise as a paradoxical side effect of antiTNF treatment. Methods: The article reports on three patients with Crohn’s disease who developed hidradenitis suppurativa during the treatment with adalimumab. Results: Case 1: A 38-year-old female exhibited an infiltrative lesion in the inguinal region and vulva, consistent with hidradenitis suppurativa, after three months of adalimumab. These lesions were treated with partial vulvectomy. Case 2: After adalimumab treatment, a 27-year-old female, originally diagnosed with ileocolonic Crohn’s disease, went into clinical and endoscopic remission. The patient eventually presented two hyperchromic nodules in the inguinal region, which were diagnosed as hidradenitis suppurativa. The patient showed improvement after treatment with oral doxycycline and local therapy. Case 3: A 34-year-old female with fistulizing and stenosing ileocolonic Crohn’s disease, started adalimumab in 2010, with optimization in 2015. One year after, the patient developed bilateral, erythematous, hardened, inguinal nodulations with purulent drainage, consistent with hidradenitis suppurativa. Treatment with oral doxycycline, fusidic acid, and infiltration with triamcinolone resulted in partial improvement of the lesions. In 2018, the lesions deteriorate. The patient underwent surgical treatment. Conclusion: Patients with inflammatory bowel disease are more likely to the development of other mediated inflammatory diseases, such as hidradenitis suppurativa. Hidradenitis suppurativa may appear as a paradoxical reaction to anti-TNF therapy. Clinical teams must be aware of this type of complication. Early diagnosis and treatment are essential for controlling the disease and preventing the onset of complications.Department of Internal Medicine São Paulo State University (Unesp) Medical SchoolInflammatory Bowel Disease Unit Saint Mark’s HospitalDepartment of Surgery São Paulo State University (Unesp) Medical SchoolDepartment of Internal Medicine São Paulo State University (Unesp) Medical SchoolDepartment of Surgery São Paulo State University (Unesp) Medical SchoolUniversidade Estadual Paulista (Unesp)Saint Mark’s HospitalBeraldo, Rodrigo Fedatto [UNESP]Marcondes, Mariana Barros [UNESP]Baima, Julio Pinheiro [UNESP]Barros, Jaqueline Ribeiro [UNESP]Ramdeen, MadhoorSaad-Hossne, Rogerio [UNESP]Sassaki, Ligia Yukie [UNESP]2020-12-12T02:19:13Z2020-12-12T02:19:13Z2020-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article293-298http://dx.doi.org/10.2147/CEG.S263685Clinical and Experimental Gastroenterology, v. 13, p. 293-298.1178-7023http://hdl.handle.net/11449/20090810.2147/CEG.S2636852-s2.0-85089496831Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengClinical and Experimental Gastroenterologyinfo:eu-repo/semantics/openAccess2024-08-14T17:36:30Zoai:repositorio.unesp.br:11449/200908Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T17:36:30Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? |
title |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? |
spellingShingle |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? Beraldo, Rodrigo Fedatto [UNESP] Adalimumab Crohn’s disease Hidradenitis suppurativa Inflammatory bowel disease Beraldo, Rodrigo Fedatto [UNESP] Adalimumab Crohn’s disease Hidradenitis suppurativa Inflammatory bowel disease |
title_short |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? |
title_full |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? |
title_fullStr |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? |
title_full_unstemmed |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? |
title_sort |
Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with crohn’s disease? |
author |
Beraldo, Rodrigo Fedatto [UNESP] |
author_facet |
Beraldo, Rodrigo Fedatto [UNESP] Beraldo, Rodrigo Fedatto [UNESP] Marcondes, Mariana Barros [UNESP] Baima, Julio Pinheiro [UNESP] Barros, Jaqueline Ribeiro [UNESP] Ramdeen, Madhoor Saad-Hossne, Rogerio [UNESP] Sassaki, Ligia Yukie [UNESP] Marcondes, Mariana Barros [UNESP] Baima, Julio Pinheiro [UNESP] Barros, Jaqueline Ribeiro [UNESP] Ramdeen, Madhoor Saad-Hossne, Rogerio [UNESP] Sassaki, Ligia Yukie [UNESP] |
author_role |
author |
author2 |
Marcondes, Mariana Barros [UNESP] Baima, Julio Pinheiro [UNESP] Barros, Jaqueline Ribeiro [UNESP] Ramdeen, Madhoor Saad-Hossne, Rogerio [UNESP] Sassaki, Ligia Yukie [UNESP] |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) Saint Mark’s Hospital |
dc.contributor.author.fl_str_mv |
Beraldo, Rodrigo Fedatto [UNESP] Marcondes, Mariana Barros [UNESP] Baima, Julio Pinheiro [UNESP] Barros, Jaqueline Ribeiro [UNESP] Ramdeen, Madhoor Saad-Hossne, Rogerio [UNESP] Sassaki, Ligia Yukie [UNESP] |
dc.subject.por.fl_str_mv |
Adalimumab Crohn’s disease Hidradenitis suppurativa Inflammatory bowel disease |
topic |
Adalimumab Crohn’s disease Hidradenitis suppurativa Inflammatory bowel disease |
description |
Background: Hidradenitis suppurativa is a chronic inflammatory skin disorder associated with inflammatory bowel disease. However, it can arise as a paradoxical side effect of antiTNF treatment. Methods: The article reports on three patients with Crohn’s disease who developed hidradenitis suppurativa during the treatment with adalimumab. Results: Case 1: A 38-year-old female exhibited an infiltrative lesion in the inguinal region and vulva, consistent with hidradenitis suppurativa, after three months of adalimumab. These lesions were treated with partial vulvectomy. Case 2: After adalimumab treatment, a 27-year-old female, originally diagnosed with ileocolonic Crohn’s disease, went into clinical and endoscopic remission. The patient eventually presented two hyperchromic nodules in the inguinal region, which were diagnosed as hidradenitis suppurativa. The patient showed improvement after treatment with oral doxycycline and local therapy. Case 3: A 34-year-old female with fistulizing and stenosing ileocolonic Crohn’s disease, started adalimumab in 2010, with optimization in 2015. One year after, the patient developed bilateral, erythematous, hardened, inguinal nodulations with purulent drainage, consistent with hidradenitis suppurativa. Treatment with oral doxycycline, fusidic acid, and infiltration with triamcinolone resulted in partial improvement of the lesions. In 2018, the lesions deteriorate. The patient underwent surgical treatment. Conclusion: Patients with inflammatory bowel disease are more likely to the development of other mediated inflammatory diseases, such as hidradenitis suppurativa. Hidradenitis suppurativa may appear as a paradoxical reaction to anti-TNF therapy. Clinical teams must be aware of this type of complication. Early diagnosis and treatment are essential for controlling the disease and preventing the onset of complications. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-12T02:19:13Z 2020-12-12T02:19:13Z 2020-01-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.2147/CEG.S263685 Clinical and Experimental Gastroenterology, v. 13, p. 293-298. 1178-7023 http://hdl.handle.net/11449/200908 10.2147/CEG.S263685 2-s2.0-85089496831 |
url |
http://dx.doi.org/10.2147/CEG.S263685 http://hdl.handle.net/11449/200908 |
identifier_str_mv |
Clinical and Experimental Gastroenterology, v. 13, p. 293-298. 1178-7023 10.2147/CEG.S263685 2-s2.0-85089496831 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Clinical and Experimental Gastroenterology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
293-298 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1822231848527331328 |
dc.identifier.doi.none.fl_str_mv |
10.2147/CEG.S263685 |